Potassium 관련 부정맥

C 근거 소규모 연구에서의 근거는 제한적이지만, 일부 긍정적인 신호가 존재합니다.

Hypokalemia is a well-established arrhythmia trigger. Guidelines support maintaining serum K+ >4.0 mEq/L. Research on supplementation benefit in normokalemic patients is unclear.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'heartcited.com'; const params = 'ingredient\u003Dpotassium\u0026condition\u003Darrhythmia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

결론

Hypokalemia is a well-established arrhythmia trigger. Guidelines support maintaining serum K+ >4.0 mEq/L. Research on supplementation benefit in normokalemic patients is unclear.

Key Study Findings

Other n=19 1 weeks

Effect of moderate potassium-elevating treatment in long QT syndrome: the TriQarr Potassium Study.

Dose: 50 mg vs: baseline Outcome: cardiac repolarisation 효과: None p=0.07

대상 집단: lqts with a disease-causing kcnq1 or kcnh2 variant

Cohort Study n=157766 26.0 weeks

Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a …

Dose: None vs: None Outcome: Incidence of hyperkalemia, mortality 효과: None None

대상 집단: Newly diagnosed CKD patients in Denmark

Observational Study n=40

Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1).

Dose: anti-digoxin antibodies (Fab) vs: pre-treatment Outcome: serum digoxin and clinical outcomes 효과: Fab bound digoxin; no improved clinical outcomes None

대상 집단: Chronic digoxin toxicity patients

Other

Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, …

Dose: None vs: None Outcome: None 효과: None None

대상 집단: None

Other

Potassium supplements or potassium-sparing agents.

Dose: None vs: None Outcome: mineral status 효과: None None

대상 집단: hypertensive patients

Key Statistics

연구

300

참여자

↑

Positive

등급

Referenced Papers

Effect of moderate potassium-elevating treatment in long QT syndrome: the TriQarr Potassium Study. Other

Open heart 2021 6 인용

Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study. Other

Nephrology, dialysis, transplantation … 2018 83 인용

Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1). Observational

Clinical toxicology (Philadelphia, … 2016 25 인용

Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common … Other

Therapeutic drug monitoring 2011 17 인용

Potassium supplements or potassium-sparing agents. Other

Acta pharmacologica et … 1984 3 인용

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

일반적으로 사용되는 용량

supplements:: Typically 99 mg/dose (FDA limit per unit)
dashdiettarget:: 4,700 mg/day
whorecommendation:: 3,510 mg/day from food

상한량: No UL for dietary potassium in healthy individuals; supplemental potassium should be supervised

연구에서 사용된 용량

용량	기간	효과	N
50 mg	1 weeks	Neutral	19
None	26.0 weeks	Mixed	157766
anti-digoxin antibodies (Fab)	--	Neutral	40
None	--	Positive	--
None	--	Mixed	--

권장 복용 시간: With meals to reduce GI irritation; divide supplemental doses throughout the day

Safety & Side Effects

보고된 부작용

⚠ Gastrointestinal irritation (nausea, vomiting, diarrhea)
⚠ Hyperkalemia risk in patients with renal impairment
⚠ Cardiac arrhythmias at excessively high serum levels

알려진 상호작용

● ACE inhibitors (increased hyperkalemia risk)
● ARBs (increased hyperkalemia risk)
● Potassium-sparing diuretics (increased hyperkalemia risk)
● NSAIDs (may increase potassium retention)

일일 최대 섭취 허용량: No UL for dietary potassium in healthy individuals; supplemental potassium should be supervised

건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.

Frequently Asked Questions

Does Potassium help with 부정맥?

Based on 5 studies with 300 participants, there is limited but promising evidence that Potassium may support 부정맥 management. Our evidence grade is C (Some Evidence).

How much Potassium should I take for 부정맥?

Studies have used various dosages. A commonly studied range is Typically 99 mg/dose (FDA limit per unit). Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Potassium?

Reported side effects may include Gastrointestinal irritation (nausea, vomiting, diarrhea), Hyperkalemia risk in patients with renal impairment, Cardiac arrhythmias at excessively high serum levels. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Potassium and 부정맥?

We rate the evidence as Grade C (Some Evidence). This rating is based on 5 peer-reviewed studies with 300 total participants. The overall direction of effect is positive.

Potassium 다른 건강 상태에 대한 근거

고혈압 B

한눈에 보기

Hypokalemia is a well-established arrhythmia trigger. Guidelines support maintaining serum K+ >4.0 mEq/L. Research on supplementation benefit in normokalemic patients is unclear.

Evidence Strength52%

Moderate confidence

연구 분석

RCT (0)Meta (0)Other (5)

대안 비교

이 건강 상태에 대한 다른 성분의 비교 결과를 확인하세요.

모든 성분 보기: 부정맥

자세히 알아보기

References

[1] Peter Marstrand et al.. Open Heart. 2021. Effect of moderate potassium-elevating treatment in long QT syndrome: the TriQarr Potassium Study. doi:10.1136/openhrt-2021-001670 PubMed
[2] Reimar W Thomsen et al.. Nephrol Dial Transplant. 2018. Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study. doi:10.1093/ndt/gfx312 PubMed
[3] Betty S Chan et al.. Clin Toxicol (Phila). 2016. Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1). doi:10.1080/15563650.2016.1175620 PubMed
[4] Andrea DeFrance et al.. Ther Drug Monit. 2011. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common … doi:10.1097/FTD.0b013e3181fd4c30 PubMed
[5] S Persson. Acta Pharmacol Toxicol (Copenh). 1984. Potassium supplements or potassium-sparing agents. doi:10.1111/j.1600-0773.1984.tb03642.x PubMed

FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.

Potassium 관련 부정맥

Embed This Widget

결론

Key Study Findings

Key Statistics

Referenced Papers

Dosage & Usage

일반적으로 사용되는 용량

연구에서 사용된 용량

Safety & Side Effects

보고된 부작용

알려진 상호작용

Frequently Asked Questions

Related Evidence

관련 다른 성분: 부정맥

Potassium 다른 건강 상태에 대한 근거

References